Wedbush maintains Outperform rating on Xencor, $45 price target
Wedbush kept its Outperform rating on Xencor with a $45 price target, suggesting 54.2% upside from the last close. XmAb819 showed 45% ORR in ccRCC trials, supporting accelerated approval. Xencor plans global studies and FDA discussions for market share.
How this was made
The 30-second read
Why it matters
The analyst upgrade reflects confidence in XmAb819's path to market, which could materially affect Xencor's valuation.
Market read
The news provides a fresh catalyst for Xencor, offering traders a clear buy signal based on upgraded target and trial data.
What to watch
Potential competition from other renal‑cancer therapies and reimbursement uncertainties.
Background
Xencor is a clinical‑stage biotech focused on engineered antibody therapeutics.
Ticker impact
Wedbush upgraded Xencor to Outperform with a $45 price target after positive Phase 2 data for XmAb819 in renal cancer.
likely upward pressure as investors price in the 54% upside target.
The new efficacy data and accelerated‑approval pathway increase commercial potential, prompting a bullish rating.
Market effects
Positive data may lift other biotech firms developing oncology antibodies.
US biotech sector could see modest gains.
Limited to biotech investors worldwide.
Counterpoint
If the FDA does not grant accelerated approval, the upside could be limited.
Key entities
- companyXencor Inc.
Developer of XmAb819 antibody.
- analystWedbush Securities
Equity research firm issuing the Outperform rating.
